UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
or

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
71.71 -0.08 (-0.11%) 04/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 71.25 -0.46 (-0.64%) 19:54 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
69.56
Day High
73.16
Open 72.35
Previous Close 71.79 71.79
Volume 1,279,500 1,279,500
Avg Vol 2,638,875 2,638,875
Stochastic %K 53.03% 53.03%
Weighted Alpha +134.74 +134.74
5-Day Change +9.47 (+15.22%) +9.47 (+15.22%)
52-Week Range 22.28 - 117.33 22.28 - 117.33
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,854,698
  • Shares Outstanding, K 105,503
  • Annual Sales, $ 675,040 K
  • Annual Income, $ 141,210 K
  • EBIT $ 137 M
  • EBITDA $ 127 M
  • 60-Month Beta 0.15
  • Price/Sales 11.21
  • Price/Cash Flow 57.74
  • Price/Book 11.06

Options Overview Details

View History
  • Implied Volatility 71.85% ( -2.64%)
  • Historical Volatility 230.96%
  • IV Percentile 56%
  • IV Rank 40.57%
  • IV High 156.92% on 05/17/24
  • IV Low 13.78% on 08/16/24
  • Put/Call Vol Ratio 0.50
  • Today's Volume 512
  • Volume Avg (30-Day) 3,285
  • Put/Call OI Ratio 1.13
  • Today's Open Interest 39,084
  • Open Int (30-Day) 50,012

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.17
  • Number of Estimates 4
  • High Estimate 0.18
  • Low Estimate 0.15
  • Prior Year 0.25
  • Growth Rate Est. (year over year) -32.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
53.79 +33.31%
on 03/28/25
Period Open: 58.32
117.33 -38.88%
on 03/31/25
+13.39 (+22.96%)
since 03/25/25
3-Month
52.45 +36.72%
on 03/07/25
Period Open: 59.99
117.33 -38.88%
on 03/31/25
+11.72 (+19.54%)
since 01/24/25
52-Week
22.28 +221.86%
on 04/26/24
Period Open: 22.21
117.33 -38.88%
on 03/31/25
+49.50 (+222.87%)
since 04/25/24

Most Recent Stories

More News
SoundHound AI, Domo, Plug Power, Corcept, and 8x8 Shares Are Falling, What You Need To Know

SoundHound AI, Domo, Plug Power, Corcept, and 8x8 Shares Are Falling, What You Need To Know

CORT : 71.71 (-0.11%)
SOUN : 9.52 (+1.49%)
PLUG : 0.8116 (-4.36%)
DOMO : 7.50 (+2.46%)
EGHT : 1.8200 (+4.00%)
3 Biopharmaceutical Stocks Bucking the Sell-Off

Three biopharma companies may appeal to investors looking for firms that have not been rocked by tariff-inspired turbulence.

CORT : 71.71 (-0.11%)
DBVT : 8.53 (-4.16%)
SLRN : 2.17 (unch)
ABBV : 186.06 (+3.15%)
ALMS : 4.28 (-0.70%)
Q4 Earnings Highs And Lows: Eli Lilly (NYSE:LLY) Vs The Rest Of The Branded Pharmaceuticals Stocks

Q4 Earnings Highs And Lows: Eli Lilly (NYSE:LLY) Vs The Rest Of The Branded Pharmaceuticals Stocks

CORT : 71.71 (-0.11%)
SUPN : 32.22 (+2.78%)
LLY : 884.54 (+2.89%)
ZTS : 153.47 (+0.77%)
BMY : 47.90 (-1.62%)
Q4 Earnings Roundup: Organon (NYSE:OGN) And The Rest Of The Branded Pharmaceuticals Segment

Q4 Earnings Roundup: Organon (NYSE:OGN) And The Rest Of The Branded Pharmaceuticals Segment

CORT : 71.71 (-0.11%)
OGN : 12.20 (+0.66%)
SUPN : 32.22 (+2.78%)
MRK : 82.74 (+3.63%)
ZTS : 153.47 (+0.77%)
SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States

Sanofi SNY and partner, Alnylam Pharmaceuticals ALNY, announced that the FDA has approved Qfitlia (fitusiran) as the first antithrombin-lowering (AT) therapy for routine prophylaxis to prevent or reduce...

BAYRY : 6.6100 (+2.80%)
CORT : 71.71 (-0.11%)
ALNY : 251.56 (+3.69%)
SNY : 52.32 (-2.28%)
Why Is Corcept (CORT) Stock Soaring Today

Why Is Corcept (CORT) Stock Soaring Today

CORT : 71.71 (-0.11%)
3 Reasons to Sell CORT and 1 Stock to Buy Instead

3 Reasons to Sell CORT and 1 Stock to Buy Instead

CORT : 71.71 (-0.11%)
TDG : 1,378.13 (+0.74%)
3 Growth Stocks in Hot Water

3 Growth Stocks in Hot Water

CORT : 71.71 (-0.11%)
NX : 16.41 (-1.14%)
SEM : 17.35 (+4.64%)
1 Small-Cap Stock on Our Buy List and 2 to Avoid

1 Small-Cap Stock on Our Buy List and 2 to Avoid

CORT : 71.71 (-0.11%)
SEMR : 10.33 (+1.18%)
NYT : 51.21 (+1.19%)
Corcept Shares Rise More Than 55% in 6 Months: Here's Why

Shares of Corcept Therapeutics Incorporated CORT have rallied 56.4% in the past six months against the industry’s decline of 10.5%.The company’s sole-marketed drug, Korlym (mifepristone), which is...

CORT : 71.71 (-0.11%)
JAZZ : 110.80 (+1.67%)
ANIP : 69.82 (+0.26%)
ORGO : 4.56 (+0.66%)
Are Options Traders Betting on a Big Move in Corcept Therapeutics (CORT) Stock?

Investors in Corcept Therapeutics Incorporated CORT need to pay close attention to the stock based on moves in the options market lately. That is because the March 21, 2025 $20 Call had some of the highest...

CORT : 71.71 (-0.11%)
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks

Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks

CORT : 71.71 (-0.11%)
RPRX : 32.20 (+0.53%)
SUPN : 32.22 (+2.78%)
OGN : 12.20 (+0.66%)
ZTS : 153.47 (+0.77%)
Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers

Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers

CORT : 71.71 (-0.11%)
SUPN : 32.22 (+2.78%)
MRK : 82.74 (+3.63%)
ZTS : 153.47 (+0.77%)
BMY : 47.90 (-1.62%)
Why Corcept (CORT) Shares Are Sliding Today

Why Corcept (CORT) Shares Are Sliding Today

CORT : 71.71 (-0.11%)
Corcept: Q4 Earnings Snapshot

Corcept: Q4 Earnings Snapshot

CORT : 71.71 (-0.11%)
Corcept (NASDAQ:CORT) Reports Sales Below Analyst Estimates In Q4 Earnings

Corcept (NASDAQ:CORT) Reports Sales Below Analyst Estimates In Q4 Earnings

CORT : 71.71 (-0.11%)
Corcept (CORT) Q4 Earnings Report Preview: What To Look For

Corcept (CORT) Q4 Earnings Report Preview: What To Look For

CORT : 71.71 (-0.11%)
LLY : 884.54 (+2.89%)
PFE : 22.92 (+0.61%)
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol

For Immediate ReleaseChicago, IL – February 3, 2025 – Today, Zacks Equity Research discusses Corcept Therapeutics CORT, Amneal Pharmaceuticals AMRX, Dyne Therapeutics DYN, Nektar Therapeutics NKTR...

CORT : 71.71 (-0.11%)
DYN : 11.06 (-0.45%)
CRDL : 1.0800 (+0.93%)
AMRX : 7.48 (+0.81%)
NKTR : 0.7751 (+4.98%)
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era

The biotech industry has declined since Donald Trump’s election victory. This was mainly because Trump nominated Robert F. Kennedy Jr., a vaccine skeptic, to head the Health and Human Services, the agency...

CORT : 71.71 (-0.11%)
DYN : 11.06 (-0.45%)
CRDL : 1.0800 (+0.93%)
AMRX : 7.48 (+0.81%)
NKTR : 0.7751 (+4.98%)
Zacks.com featured highlights include OppFi, Corcept Therapeutics, DXP Enterprises, Perpetua Resources and Graham

For Immediate ReleaseChicago, IL – January 30, 2025 – Stocks in this week’s article are OppFi Inc. OPFI, Corcept Therapeutics Inc. CORT, DXP Enterprises Inc. DXPE, Perpetua Resources Corp. PPTA and...

CORT : 71.71 (-0.11%)
OPFI : 9.27 (-1.07%)
PPTA : 14.29 (-0.07%)
DXPE : 85.40 (+0.47%)
GHM : 31.54 (-0.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Corcept is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders which are associated with the activity of the hormone cortisol, also known as the stress hormone. Corcept's only marketed drug, Korlym (mifepristone),...

See More

Key Turning Points

3rd Resistance Point 76.99
2nd Resistance Point 75.08
1st Resistance Point 73.39
Last Price 71.71
1st Support Level 69.79
2nd Support Level 67.88
3rd Support Level 66.19

See More

52-Week High 117.33
Fibonacci 61.8% 81.02
Last Price 71.71
Fibonacci 50% 69.81
Fibonacci 38.2% 58.59
52-Week Low 22.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.